Valsartan is a specific angiotensin Ⅱ (AT1) receptor antagonist. It is also a non skin AT1 receptor antagonist after losartan. It plays a key role in regulating systemic blood pressure and maintaining electrolyte and body fluid balance. It selectively acts on AT1 receptor subtypes and blocks the binding of Ang Ⅱ to AT1 receptor (its specific antagonistic effect against AT1 receptor is about 20000 times greater than that of AT2 receptor), thus inhibiting vasoconstriction and aldosterone release, resulting in hypotensive effect, but not inhibiting aldosterone release induced by potassium ion (K +). The antihypertensive effect is superior to enalapril in the treatment of hypertension, mild to moderate essential hypertension, especially for secondary hypertension caused by kidney damage. It can significantly reduce proteinuria in hypertensive patients with normal diabetes or normal renal function, and has the protective effect of promoting uric acid and urinary sodium excretion. It is also suitable for reducing the cardiovascular mortality of high-risk patients (left ventricular failure or left ventricular dysfunction) after heart attack.